Lilly's Anti-IL-17 Monoclonal Antibody, Ixekizumab, Met Primary Endpoint in Phase II Study in Patients With Chronic Plaque Psoriasis

New Phase II data, published today in the New England Journal of Medicine, showed that Eli Lilly and Company's

ixekizumab (pronounced ix" e kiz' ue mab, previously known as LY2439821), an anti-IL-17 monoclonal antibody, met its primary endpoint in patients with moderate-to-severe plaque psoriasis, with significantly more patients achieving at least a 75 percent improvement in Psoriasis Area and Severity Index scores from baseline compared with placebo at week 12. Approximately 40 percent of patients in the two highest dose groups had complete clearance of psoriasis plaques on the skin, as reflected by a reduction in the PASI score by 100 percent or an sPGA score of 0 at 12 weeks.